JCS/T2D - We are advocates. We learn. We share. We inform.

Abstract

An international research team led by Lund University Diabetes Centre has discovered blood-based epigenetic markers that may help predict which people with type 2 diabetes are at risk of serious cardiovascular events. In a study of 752 newly diagnosed participants followed for just over seven years, a scoring tool based on DNA methylation patterns outperformed standard clinical risk calculators, particularly in ruling out low-risk individuals. While further validation is needed, this approach could lead to a simple blood test that supports more personalized prevention and treatment strategies in type 2 diabetes care.

Key Points

• Study Scope: Followed 752 newly diagnosed type 2 diabetes patients for an average of 4 years, identifying 102 major cardiovascular events.
• Main Finding: Developed a DNA methylation-based score using 87 sites that predicted heart risk more accurately than standard clinical risk scores.
• Low-Risk Identification: The tool had a 96% probability of correctly identifying those unlikely to develop cardiovascular disease.
• Limitations: Short follow-up period, limited diversity, moderate positive predictive value, and missing lifestyle data.
• Future Potential: Could evolve into a simple blood test to guide personalized prevention, treatment, and follow-up in type 2 diabetes.

Abstract

Researchers have identified two proteins, RORDEP1 and RORDEP2, produced by certain strains of the gut bacterium Ruminococcus torques, that influence weight, blood sugar, and bone health. Preclinical studies show they increase GLP-1 and PYY, reduce GIP, boost fat burning, and improve liver insulin sensitivity. Early human trials are underway, exploring their potential as next-generation probiotics or protein-based therapies for type 2 diabetes, obesity, and related conditions.

Key Points

• RORDEP1 and RORDEP2 mimic some effects of the exercise hormone irisin and modulate key metabolic hormones.
• Animal studies show reduced weight gain, improved glucose tolerance, and stronger bones with RORDEP treatment.
• Mechanisms include increased satiety hormones, direct fat-burning effects, and improved hepatic insulin sensitivity.
• Potential therapeutic uses range from preventive probiotics to drug combinations enhancing GLP-1 therapy.
• Human trials have started, but clinical availability is likely 10–15 years away.

Abstract

mRNA vaccines work by delivering temporary instructions that help the body produce a harmless protein and build immune protection—without using live viruses or altering DNA. Backed by decades of research, this approach offers a safe, flexible alternative to traditional vaccines. Clear explanations dispel common misconceptions and highlight how mRNA technology could one day support treatments for chronic conditions like type 2 diabetes.

Key Points

• mRNA is a natural process your body uses every day to make proteins; mRNA vaccines simply provide instructions to produce one harmless protein to trigger immune protection.
• mRNA cannot alter DNA or cause infection — it never enters the cell nucleus and breaks down shortly after delivering its message.
• Lipid nanoparticles (LNPs) protect fragile mRNA and help it enter cells safely, allowing for effective delivery without long-term presence in the body.
• The platform behind mRNA vaccines was built on decades of research, enabling rapid, flexible responses to health threats — including potential future use in metabolic disorders.
• Clear communication and fact-based explanations are essential to combat misinformation and help people make informed decisions about mRNA technology.